Evidence map›Paper›PMID 38872398›Full record

ArticleCancer medicine2024

Internal validation of Automated Visual Evaluation (AVE) on smartphone images for cervical cancer screening in a prospective study in Zambia.

Liming Hu, Mulindi H Mwanahamuntu, Vikrant V Sahasrabuddhe, Caroline Barrett, Matthew P Horning, Ishan Shah, Zohreh Laverriere, Dipayan Banik, Ye Ji, Aaron Lunda Shibemba and 7 more

Abstract readValidation Study
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. The Future of Cervical Cancer Screening.International journal of women's health · 2024
    Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Liming HuGlobal Health Labs, Inc., Bellevue, Washington, USA.ORCID 0009-0004-9560-7709
Mulindi H MwanahamuntuUniversity Teaching Hospital, Lusaka, Zambia.
Vikrant V SahasrabuddheNational Cancer Institute, NIH, Bethesda, Maryland, USA.
Caroline BarrettClinton Health Access Initiative (CHAI), Inc.,, Boston, Massachusetts, USA.
Matthew P HorningGlobal Health Labs, Inc., Bellevue, Washington, USA.
Ishan ShahGlobal Health Labs, Inc., Bellevue, Washington, USA.
Zohreh LaverriereGlobal Health Labs, Inc., Bellevue, Washington, USA.
Dipayan BanikGlobal Health Labs, Inc., Bellevue, Washington, USA.
Ye JiGlobal Health Labs, Inc., Bellevue, Washington, USA.
Aaron Lunda ShibembaUniversity Teaching Hospital, Lusaka, Zambia.
Samson ChiseleUniversity Teaching Hospital, Lusaka, Zambia.
Mukatimui Kalima MunalulaUniversity Teaching Hospital, Lusaka, Zambia.
Friday KaungaUniversity Teaching Hospital, Lusaka, Zambia.
Francis MusondaUniversity Teaching Hospital, Lusaka, Zambia.
Evans MalyanguUniversity Teaching Hospital, Lusaka, Zambia.
Karen Milch HariharanClinton Health Access Initiative (CHAI), Inc.,, Boston, Massachusetts, USA.
Groesbeck P ParhamUniversity Teaching Hospital, Lusaka, Zambia.

Funding

Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries -admin supplementUH3CA202721 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI BASU, PARTHA · 2018 to 2023
$3.2M
Global Health Labs, Inc (www.ghlabs.org)NCI NIH HHS UH3 CA202721UnitaidUS National Cancer Institute UH3CA202721
6 · The paper itself

Abstract

objectivesVisual inspection with acetic acid (VIA) is a low-cost approach for cervical cancer screening used in most low- and middle-income countries (LMICs) but, similar to other visual tests, is subjective and requires sustained training and quality assurance. We developed, trained, and validated an artificial-intelligence-based "Automated Visual Evaluation" (AVE) tool that can be adapted to run on smartphones to assess smartphone-captured images of the cervix and identify precancerous lesions, helping augment VIA performance.

designProspective study.

settingEight public health facilities in Zambia.

participantsA total of 8204 women aged 25-55.

interventionsCervical images captured on commonly used low-cost smartphone models were matched with key clinical information including human immunodeficiency virus (HIV) and human papillomavirus (HPV) status, plus histopathology analysis (where applicable), to develop and train an AVE algorithm and evaluate its performance for use as a primary screen and triage test for women who are HPV positive.

main outcome measuresArea under the receiver operating curve (AUC); sensitivity; specificity.

resultsAs a general population screening tool for cervical precancerous lesions, AVE identified cases of cervical precancerous and cancerous (CIN2+) lesions with high performance (AUC = 0.91, 95% confidence interval [CI] = 0.89-0.93), which translates to a sensitivity of 85% (95% CI = 81%-90%) and specificity of 86% (95% CI = 84%-88%) based on maximizing the Youden's index. This represents a considerable improvement over naked eye VIA, which as per a meta-analysis by the World Health Organization (WHO) has a sensitivity of 66% and specificity of 87%. For women living with HIV, the AUC of AVE was 0.91 (95% CI = 0.88-0.93), and among those testing positive for high-risk HPV types, the AUC was 0.87 (95% CI = 0.83-0.91).

conclusionsThese results demonstrate the feasibility of utilizing AVE on images captured using a commonly available smartphone by nurses in a screening program, and support our ongoing efforts for moving to more broadly evaluate AVE for its clinical sensitivity, specificity, feasibility, and acceptability across a wider range of settings. Limitations of this study include potential inflation of performance estimates due to verification bias (as biopsies were only obtained from participants with visible aceto-white cervical lesions) and due to this being an internal validation (the test data, while independent from that used to develop the algorithm was drawn from the same study).

Indexed as

Early Detection of CancerSmartphoneUterine Cervical NeoplasmsAdultAlgorithmsArtificial IntelligenceFemaleHumansMass ScreeningMiddle AgedPapillomavirus InfectionsProspective StudiesROC CurveSensitivity and SpecificityUterine Cervical DysplasiaZambiacancer preventioncancer risk factorsdeep learningepidemiology and preventiongynecological oncologymachine learningstatistical methodswomen's cancer

Identifiers

PMID38872398
PMCPMC11176573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.